Concepedia

Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype

Eduardo Martínez de Dueñas, Enrique Ochoa Aranda, Teresa Ferrer Magdalena, Fernando Bandrés, Luis Miguel Chicharro García, José A. Gómez Capilla, Mercedes Zafra Ceres, Tomás de Haro, Regina Romero Llorens, C. Ferrer Albiach,

The Breast · 2014 · 53 citations · 26 references

DOI

Concepts

References

26

CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment

Zeruesenay Desta, Vered Stearns, Brent B. Ward et al. · JNCI Journal of the National Cancer Institute · 2005 · 942 citations · Full text

, , +17

Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine

Vered Stearns · JNCI Journal of the National Cancer Institute · 2003 · 849 citations · Full text

, , +17

Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes

Matthew P. Goetz, James M. Rae, Vera J. Suman et al. · Journal of Clinical Oncology · 2005 · 786 citations · Full text

, , +16

Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen

Werner Schroth · JAMA · 2009 · 529 citations · Full text

, , +17

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment

Sandra Regina de Oliveira Borges, Zereunesay Desta, L LI et al. · Clinical Pharmacology & Therapeutics · 2006 · 479 citations · Full text

, , +17